Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
Wanlapakorn N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, Thongmee T, Vichaiwattana P, Auphimai C, Wongsrisang L, Klinfueng S, Sudhinaraset N, Poovorawan Y. Wanlapakorn N, et al. Among authors: phowatthanasathian h. Vaccine. 2022 May 20;40(23):3203-3209. doi: 10.1016/j.vaccine.2022.04.043. Epub 2022 Apr 18. Vaccine. 2022. PMID: 35465981 Free PMC article.
Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.
Wanlapakorn N, Kanokudom S, Phowatthanasathian H, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, Vichaiwattana P, Klinfueng S, Thongmee T, Aeemjinda R, Khanarat N, Srimuan D, Thatsanatorn T, Chantima W, Pakchotanon P, Duangchinda T, Sudhinaraset N, Poovorawan Y. Wanlapakorn N, et al. Among authors: phowatthanasathian h. J Med Virol. 2023 May;95(5):e28758. doi: 10.1002/jmv.28758. J Med Virol. 2023. PMID: 37212319
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
Yorsaeng R, Suntronwong N, Phowatthanasathian H, Assawakosri S, Kanokudom S, Thongmee T, Vichaiwattana P, Auphimai C, Wongsrisang L, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Yorsaeng R, et al. Among authors: phowatthanasathian h. Vaccine. 2022 Jan 24;40(3):524-530. doi: 10.1016/j.vaccine.2021.11.083. Epub 2021 Dec 3. Vaccine. 2022. PMID: 34893344 Free PMC article.
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study.
Wanlapakorn N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, Vichaiwattana P, Thongmee T, Auphimai C, Srimuan D, Thatsanatorn T, Assawakosri S, Kanokudom S, Poovorawan Y. Wanlapakorn N, et al. Among authors: phowatthanasathian h. Hum Vaccin Immunother. 2022 Dec 31;18(1):2029111. doi: 10.1080/21645515.2022.2029111. Epub 2022 Feb 24. Hum Vaccin Immunother. 2022. PMID: 35209809 Free PMC article.
Neutralizing antibodies against Omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity.
Suntronwong N, Kanokudom S, Assawakosri S, Vichaiwattana P, Klinfueng S, Phowatthanasathian H, Chansaenroj J, Srimuan D, Thatsanathorn T, Duangchinda T, Chantima W, Pakchotanon P, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Suntronwong N, et al. Among authors: phowatthanasathian h. Int J Infect Dis. 2023 Sep;134:18-22. doi: 10.1016/j.ijid.2023.05.005. Epub 2023 May 18. Int J Infect Dis. 2023. PMID: 37207716 Free article.